NCT06529406

Prospective Evaluation of Sequencing From antiCD-20 Therapies to Ozanimod

Prospective Evaluation of Sequencing From antiCD-20 Therapies to Ozanimod (COAST: CD20 and Ozanimod Sequencing Trial)

• Status: Recruiting
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 100 (estimated)
• Sponsor: University of Colorado, Denver · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

A multi-center pilot study to evaluate safety and efficacy of ozanimod as de-escalation therapy in clinically stable MS patients previously treated with anti-CD20 therapy.

Detailed description

Multicenter, Open Label, Prospective Study examining the safety and efficacy of de-escalation therapy to ozanimod (Zeposia®) over 36 months from anti-CD20 therapy for stable patients with relapsing forms of MS. A comparison to patients continuing anti-CD20 treatment was performed with propensity scoring to a cohort of at least 500 patients followed at Cleveland Clinic and the University of Colorado who also meet the above the inclusion and exclusion criteria. Patients were followed for 36 months.

Conditions

• Relapsing Multiple Sclerosis

Interventions

Type	Name	Description
DRUG	Ozanimod	De-escalation of anti-CD20 treatment using ozanimod.

Timeline

• Start date: 2024-07-29
• Primary completion: 2028-08-01
• Completion: 2029-08-01
• First posted: 2024-07-31
• Last updated: 2025-09-18

Locations

3 sites across 1 country: United States

Regulatory

• FDA-regulated drug study